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Introduction 
 
On 20 January 2004, the Supreme Court of Canada heard an appeal by Percy Schmeiser, a 73 
year old canola farmer from Bruno, Saskatchewan, against findings that he had infringed the 
patents of the biotechnology company Monsanto. The matter raises important questions about 
gene patents, innocent infringement, and farmers’ rights. Are biological inventions patentable 
– like mechanical inventions? Can an innocent bystander be held liable for infringing a patent? 
Should farmers’ privileges to save seed trump patent rights and technology user agreements? 
 
The case concerns a Canadian patent granted to Monsanto in 1993 for an invention named 
“Glyphosate-Resistant Plants”. The patent was for “man-made genetically engineered genes, 
and cells containing those genes which, when inserted in plants, in this canola, make those 
plants resistant to glyphosate herbicides” such as Monsanto’s product Roundup Ready. 
 
In 1997, Monsanto sent private investigators – ex-Mounted Policemen – to take samples from 
the canola farm of Percy Schmeiser. It claimed that the farmer planted glyphosate-resistant 
seeds to grow a crop of GM canola, for harvest. It claimed that Schmeiser used, reproduced, 
and created genes, cells, plants and seeds containing the genes and cells claimed in the patent. 
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Both the Federal Court and the Full Federal Court held that Percy Schmeiser knew or should 
have known that those plants were glyphosate resistant when he saved their seeds in 1997 and 
planted those seeds the following year. It was the cultivation, harvest and sale of the 1998 crop 
that made Percy Schmeiser vulnerable to Monsanto’s infringement claim. 
 
As a result of the decision, Schmeiser owed Monsanto about $140,000 in judgments. He also 
had to pay substantial legal fees of $230,000. He has rented out all but 140 acres of his farm. 
Monsanto has placed a lien against the house and farm of Schmeiser. As a result, the farmer 
has raised funds from donations by supporters to help fight the considerable costs of his legal 
battles. 
 
Percy Schmeiser was supported by a group of six NGOs – including the Council of Canadians, 
the Sierra Club, and the International Center for Technology Assessment. Monsanto was 
supported by the Canadian Seed Trade Association, the Canadian Canola Growers Association, 
and the industry group BIOTECanada. 
 
The provincial government of Ontario was also a party to the case because of its concerns about 
the impact of gene patents on biomedical research and health care. The provincial government 
has taken a strong interest in the topic since it was sued by the Utah biotechnology company, 
Myriad Genetics, for infringement of the company’s patents on genetic tests for breast and 
ovarian cancer. 
 
The Supreme Court of Canada will have to consider a complex array of issues surrounding 
gene patents, innocent infringement, and farmers’ rights. There are three main areas of dispute. 
First, the court will consider whether Monsanto’s patent on “Glyphosate-Resistant Plants” is 
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valid given the prohibition on patenting high life forms in Canada. Second, the Supreme Court 
will evaluate whether Percy Schmeiser infringed the patent of Monsanto by having a patented 
GM canola crop on his land. Third, the court will consider the defence of Schmeiser that he is 
permitted under law to save and reuse seed. I will examine each of these issues in turn. 
 
Biological inventions 
 
The first area of dispute the Supreme Court of Canada will have to consider is whether 
biological inventions – such as Monsanto’s patented GM canola – are patentable subject matter. 
 
The modern patent system was a product of the industrial revolution, and designed to protect 
mechanical and chemical inventions. The regime was not designed to provide protection for 
living organisms. Indeed, life forms were considered to be discoveries of nature, rather than 
scientific inventions. 
 
However, there has been a progressive accommodation of biotechnology within the legal 
system. The French barrister Bernard Edelman summarises the evolution of the law: “Life has 
been integrated into the market as easily as could be imagined because it has been a progressive 
process.” 
 
In 1873, Louis Pasteur was granted a patent in the United States on a certain yeast, which was 
a living organism. The Plant Patent Act 1930 (US) provided limited protection for plants. The 
Plant Variety Protection Act 1970 (US) extends the category of an artificial nature to the 
reproducibility of plants. The decision of the Supreme Court of the United States in Diamond 
4 
 
v Chakrabarty determined that genetically-engineered organisms are either a manufacture or a 
composition of matter and are therefore patentable. 
 
From single-celled organisms, the line then passes through genetically engineered plants to 
oysters and transgenic animals – like Oncomouse. From there, patent offices and courts have 
been willing to grant patents on human genes and gene sequences, and stem-cell lines. 
 
However, there has been a backlash in Canada against the dramatic expansion of the scope of 
patent law. In the case of Harvard College v the Commissioner of Patents, the Supreme Court 
of Canada considered whether the transgenic animal, the Harvard Oncomouse, could be the 
subject of a patent. The Court decided by a majority of five to four that higher life forms were 
not patentable subject matter. In the leading judgment, Justice Bastarche emphasised that 
Parliament must give an express legislative direction to authorise the patenting of higher life 
forms: 
 
“Patenting higher life forms would involve a radical departure from the traditional patent 
regime. Moreover, the patentability of such life forms is a highly contentious matter that raises 
a number of extremely complex issues. If higher life forms are to be patentable, it must be 
under the clear and unequivocal direction of Parliament.” 
 
Justice Bastarche indicates that there are also a number of reasons why parliament might want 
to be cautious about encouraging the patenting of higher life forms – such as plants, seeds, 
animals, and human beings. In his view, whether higher life forms such as oncomouse ought 
to be patentable is a matter for parliament to determine. 
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The supporters of Percy Schmeiser are hopeful that the Supreme Court of Canada will overturn 
the past judgments. Nadège Adam, a biotechnology campaigner for the Council of Canadians, 
said: 
 
“We are very confident that the Supreme Court will do the right thing by reversing the Federal 
Court of Canada’s decision, and exonerating Mr. Schmeiser and all farmers. The Oncomouse 
case last December demonstrated how inadequate the federal patenting legislation is vis-à-vis 
genetic engineering.” 
 
This appeal of Percy Schmeiser has undoubtedly been strengthened by the recent decision made 
in relation to the transgenic animal oncomouse. 
 
Monsanto’s lawyer, Robert Hughes, argued that the company did not possess a patent on the 
entire canola plant, but rather an “ingredient” of the plant. Therefore, he reasoned, the 
biotechnology company did not fall foul of the prohibition against the patenting of higher life-
forms. Hughes likened the company’s patent to that of an inventor who develops a new kind 
of steel for automobiles and receives a patent for that component rather than the whole car. 
However, Justice Arbour dismissed the analogy drawn between patenting steel and a canola 
plant. She observed: “According to the Harvard mouse ruling, I don’t think the steel analogy 
works.” 
 
The Canadian biotechnology industry has been concerned that an adverse decision against 
Monsanto would jeopardise investment and venture capital to the country. Cate McCready said 
on behalf of BIOTECanada: “It was on behalf of the entire biotech community in Canada that 
we chose to intervene in order for the Court to hear the perspective of the innovators who have 
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given us more than 18,000 biotech products and processes currently under development here 
in Canada.” Biotechnology companies could invest in other jurisdictions, such as the United 
States and Australia, which provide comprehensive legal protection for gene patents. 
 
The Canadian Biotechnology Advisory Committee has released an advisory memorandum on 
“Higher Life Forms and The Patent Act”. It seeks to allay fears that the jurisprudence of the 
Supreme Court of Canada spells the ruin of the Canadian biotechnology industry. The 
Committee maintains: “If the Government of Canada wishes higher life forms to be patentable, 
it must propose amendments to the Patent Act and gain Parliament’s agreement.” It stresses 
that Canada has an unprecedented opportunity to define the special characteristics of biological 
inventions at the legislative level. 
 
Innocent infringement: from India to Australia 
 
The second are of dispute in the case is whether an innocent bystander could infringe a patent. 
 
Percy Schmeiser argued that the GM crops on his land were the result of accidental 
contamination – such as cross-field breeding by wind or insects, or by seed being blown off 
neighbour’s trucks, which did not have their tarpaulin firmly secured. In any case, he 
maintained that he did not derive any benefit from the GM canola because he did not spray it 
with Roundup Ready. 
 
Monsanto maintained that the presence of the GM canola on the farm was not accidental. It 
conducted a number of tests on canola taken from the field of Percy Schmeiser. The results of 
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these tests showed the presence of the patented gene in a range of 95-98% of the canola 
sampled. 
 
The Supreme Court of Canada heard much argument over patent infringement. There was 
much discussion over whether the mere handling of the seeds was enough to constitute a breach 
of patent rights. Justice LeBel suggested that there could be an innocent explanation for why 
Schmeiser’s field contained such a high amount of GM Canola: “There is no evidence that Mr. 
Schmeiser bought the seeds.” Justice Binnie wondered what additional profit Schmeiser made 
with Monsanto’s seeds given that the farmer had not used Roundup Ready on his crop. 
 
The Supreme Court of Canada may well fashion a defence in respect of innocent infringement 
in respect of agricultural biotechnology patents. In the Oncomouse case, Justice Bastarache 
recommended that the Patent Act 1985 (Can) contain a provision that would allow the so-called 
“innocent bystander” to rebut the usual presumption concerning knowledge of infringement in 
respect of inventions capable of reproducing, such as plants, seeds and animals 
 
Brad Sherman comments that the case poses fundamental conceptual problems for the 
operation of patent law: “One of the recurring themes in patent law has been the instability of 
biological inventions. Many of the problems they have posed for patent law can be traced to 
the fact that, unlike mechanical inventions which are inert and stable, biological inventions are 
volatile, unstable and dynamic.” 
 
The case has significant ramifications for other jurisdictions. As the Indian advocate for 
farmers rights, Vandana Shiva, has said: “Not only will that decision have a considerable 
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influence on the policy debate in Canada, but it is likely to also influence lawmakers around 
the world who are grappling with this issue.” 
 
The case has ramifications for my own home country, Australia. The Australian Law Reform 
Commission is currently investigating the impact of gene patents upon health, agriculture, and 
research. In light of the Percy Schmeiser case, the law reform body might consider whether 
Australia needs to include an innocent bystander defence and protection of farmers’ rights in 
its patent regime. 
 
Furthermore there is a need to address the potential conflict between the patent regime and the 
Gene Technology Regulator. In a similar situation to that raised by Percy Schmeiser, the Gene 
Technology Regulator would place the responsibility upon a biotechnology company to clean 
up any GM plant contamination. However, such a biotechnology company could sue a farmer 
who had patented GM plants on their land. There is a need to resolve such potential disharmony 
between the two regimes. 
 
There are also similar repercussions in the European Union. The English legal academics, 
Robert Burrell and Maria Lee, have noted: “The decision in Monsanto v Schmeiser presents us 
with the spectre of a successful action being brought against a farmer who is entirely unaware 
of the presence of the claimant’s patented genetic material, and who infringes merely by 
replanting seeds taken from these plants as part of normal farming practice.” The interaction 
between intellectual property and environmental regulation is a very vexed area, indeed. 
 
Farmers’ rights 
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The third area of dispute in the Supreme Court of Canada is about the status of farmers’ rights 
in modern agricultural economies. 
 
As was common practice for a number of canola farmers in the Bruno area, Percy Schmeiser 
routinely saved a portion of the canola harvested on his property to serve as seed for the next 
generation of crops. He observed: “My wife and I are known on the Prairies as seed developers 
in canola and as seed savers. Hundreds of thousands of farmers save their seed from year to 
year.” The farmer maintained that he was entitled to save and reuse seed under the ancient 
notion of farmers’ rights. 
 
Agricultural chemical and biotechnology companies have sought to erode farmers’ rights. They 
have attempted to limit the capacity of farmers to save and reuse seed through the means of 
patent law, contract law, and genetic use restriction technologies, in three ways. 
 
First, there is some limited recognition for the protection of farmers’ rights at a national and 
international level. The Plant Breeders Rights Act 1990 (Can) protects the right of farmers to 
save and reuse seed. However, unlike the regime of plant breeder’s rights, the Patent Act 1985 
(Can) provides no farm saved seed exception. Therefore when farmers use patented seed, they 
do not have the right to save the seed from a crop and reuse that seed in the next year. 
Accordingly, Monsanto has sued Percy Schmeiser under the general regime of patent law, 
rather than the specific system of plant breeder’s rights. As such, it maintains that Percy 
Schmeiser should not have been allowed to save and reuse patented seed. 
 
Moreover, agricultural and biotechnology companies have become increasingly reliant upon 
contract law and technology user agreements in their commercial dealings with farmers and 
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growers. The terms and conditions of such agreements are quite restrictive. Under the standard 
Monsanto agreement for canola, the growers are required to pay a technology fee and a 
premium rate for the GM seed. They are required to relinquish the right to save and reuse seed: 
 
“The Grower shall use any purchased Roundup Ready® canola seed for planting one and only 
one crop for resale for consumption. The Grower agrees not to save seed produced from 
Roundup Ready canola seed for the purpose of replanting nor to sell, give, transfer or otherwise 
convey any such seed for the purpose of replanting. The Grower also agrees not to harvest any 
volunteer Roundup Ready canola seed crops.” 
 
Second, then, the grower could only use Monsanto’s Roundup Ready brand of glyphosate 
herbicide (there are other brands). The company has the right to inspect and test their fields for 
up to three years. If any of these terms were breached, Monsanto could seek liquidated 
damages. There remains legal debate as to whether such private contacts are valid and 
enforceable, and can override the public defence to save and reuse seed. However, thus far, 
Monsanto has prevailed in legal actions for breach of contract against farmers in the United 
States. 
 
Third, agricultural chemical and biotechnology companies are investing in genetic use 
restriction technologies – known as “GURTs” for short. Such technologies render seed sterile, 
so that growers are forced to buy new seeds each year from a biotechnology company. The 
Rural Advancement Foundation International famously dubbed GURTs as “terminator 
technologies”. In a study for the Convention on Biological Diversity, Richard Jefferson and his 
collaborators comment upon the impact of genetic use technologies on intellectual property: 
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“By rendering seeds sterile if replanted a second time, a distinct effect of V-GURT technology 
is to protect the seed producer against multiplication of the seed by a third party. It may thus 
prevent the unauthorized copy of a plant variety either conventionally bred or genetically 
engineered to express a specific trait.” 
 
Thus the GURTs technology can be used to prevent infringement of plant breeder’s rights and 
patent law. Analogies could be drawn with copyright law, and the provisions banning 
circumvention devices and other technological protection measures. However, there have been 
concerns that the use of GURTs technology provides excessive protection for the holders of 
intellectual property rights. 
 
The Supreme Court of Canada may well be sympathetic to such arguments about farmers’ 
rights. In the Oncomouse case, Justice Bastarache emphasised that there is a need for farmers’ 
privilege provision to be included within the scope of the patent legislation. He envisioned that 
the privilege would permit farmers to collect and reuse seeds harvested from patented plants 
and to breed patented animals for their own use, so long as these were not sold for commercial 
breeding purposes. 
 
Similarly, the Canadian Biotechnology Advisory Committee recommended that a farmers’ 
privilege provision be included in the Patent Act 1985 (Canada). It should specify that farmers 
are permitted to save and sow seeds from patented plants or to breed patented animals, as long 
as these progeny are not sold as commercial propagating material or in a manner that 
undermines the commercial value to its creator of a genetically engineered animal, 
respectively. Further action would be necessary to ensure that farmers’ rights could not be 
overridden by contract law or technological measures. 
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An epic, unequal battle 
 
The Supreme Court of Canada has reserved its judgment in the case between Percy Schmeiser 
and Monsanto. It is difficult to predict how the judges will respond to the issues relating to 
gene patents, innocent infringement, and farmers rights. In the Oncomouse case, the Supreme 
Court of Canada was divided five to four. 
 
Trained in a civil, French legal tradition, the majority judges emphasised the ethics of patenting. 
By contrast, the minority judges from a common law, English tradition stressed the commercial 
goals of patenting. In the meantime, there has been a new appointment to the Supreme Court 
of Canada. Justice Morris Fish has replaced one of the judges in the majority in the Oncomouse 
case. This criminal lawyer from Quebec, both Anglophone and Jewish, remains an unknown 
quantity in matters of intellectual property. His judgment will prove to be decisive in the 
outcome of the appeal of Percy Schmeiser. 
 
Percy Schmeiser is a canny politician. His past experience as Mayor of Bruno has put him in 
good stead for the epic litigation. Schmeiser has run a brilliant public relations campaign, 
playing up on his plain-speaking image. He has portrayed himself as an underdog in a “David 
vs Goliath” fight. Schmeiser has jet-setted around the world, speaking to farmers, consumers, 
and environmentalists. He has polarised opinion. Schmeiser has become the unlikely folk hero 
and darling of the anti GM-crop movement. However, he has also attracted criticism from 
research and industry groups for spreading superstitious ideas about genetic technology. 
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For all the success of the public relations campaign, the legal defence of Percy Schmeiser has 
been less than convincing. His lawyer Terry Zakreski has been enthusiastic, but not necessarily 
very effective. His legal understanding of intellectual property has sometimes been 
questionable. His tortuous arguments about trespass and nuisance have fared poorly. His 
constitutional arguments were underdeveloped. Nonetheless, Percy Schmeiser could still win 
the case against Monsanto because of the recent precedent of the Supreme Court of Canada in 
the Oncomouse case. His favourable position, though, is the result of good fortune, rather than 
careful planning. 
 
In all the fuss over the litigation with Monsanto, Percy Schmeiser poses as a reluctant hero: 
 
“I got thrown into something that I never ever wanted to be in. I’d rather be fishing with my 
grandkids. But, now that I’m in it, I don’t regret the decision. I don’t want to be a hero or a 
saint but, by God, there comes a time when you’ve got to take a stand.” 
 
It remains to be seen whether his quixotic appeal in the Supreme Court of Canada will result 
in a groundbreaking precedent in patent law and biotechnology. 
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